Zalicus Inc (ZLCS)

[wildbullus]

$ZLCS Z944 was proved to have pain control property in human trial. http://finance.yahoo.com/news/zalicus-announces-positive-results-z944-123000189.html

[garyhalvo]

IMO, .90-1.00

[GMONEY4]

How low will it go...

[bikaver]

In ZLCS at around a buck.

[Andydong]

are zlcs keep droping?

[GMONEY4]

Bout time to grab a starter...

[wildbullus]

$ZLCS Does Zalicus still go to the Partnering Meeting? With Z944 P1b positive result, can Zalicus convince big pharma to partner with Zalicus?

Sentiment: Hold

[wildbullus]

$ZLCS With positive P1b result,Z944 will be in big pharma's interest?It will be hard for Zalicus proceed the Z944 alone. Buyout is possible?

[garyhalvo]

And you say this because?

[kaysmooth319]

THIS STOCK WILL BE GOING BACK UP TO 4 DOLLARS BY MID 2014

[kaysmooth319]

THIS STOCK WILL BE GOING BACK UP TO 4 DOLLARS BY MID 2014

[Disquisition]

Appears to be a bounce in progress today :)

[garyhalvo]

How would you like your toast? Slightly burnt or totally burnt?

[tweezybeezy]

Given it's history, this has happened before and had a spike about a month later. The question is, will it happen again?

[To theTop]

Its sad. I been watching this stock too.

[porgyrusty]

.18 R/S pricing today, and people wonder why investors hate R/S. And you have all these idiots who will give you one time where it worked out, and the rest are disasters. A month ago you would've back the truck up to get this stock for .18, today people are running from it, incredible.

[To theTop]

Yeah its sickening to see what happened.

[skills3]

Im sorry that happened to you guys,,,,,don't let the i told you so pricks that want to rub it in get to you,,,i see these guys on all stocks that tank,,,they love to kick people when they are down,Fn Aholes........again sorry....

[oldtimerr]

Sell what? For that you have to show potential investors that your company is worth something, and right now Z has been disappointment after disapoiment. That only way is if they successfully take Z944 all the way to phase III by itself, and that's a big maybe, after this no big pharma is gonna want to touch Z.

[wildbullus]

$ZLCS After Z160 failed, does management has the ability to move forward with Z944 into the next stage in development? Or selling company?

[porgyrusty]

Like I said, one of the best pump and dumps in awhile. Whats it trading at today, around .22 pre split pricing. What a POS.

[oldtimerr]

I said it, this one is going back to below 1, what a pain. I guess that is why they made the move to do the R/S. now the only hope for this company is Z944. Sorry for all u guys. Once I had hope for this company, but the future does not look to bright for Zalicus.

[betahighlander]

Misery- What does the t-type prospects look like?
Do they still have the cash flow from the prior products?

[surf1944]

8:30AM Zalicus reports Z160 did not meet the primary endpoint in either of the Phase 2 clinical studies; company to discontinue Z160 clinical development (ZLCS) 4.69 : Co announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.

Z160 did not meet the primary endpoint in either of the Phase 2 clinical studies in patients with lumbosacral radiculopathy (LSR) and post-herpetic neuralgia (PHN). Z160 was shown to be generally safe and well-tolerated with no drug-related serious adverse events.
Based on these results, Zalicus is discontinuing the Z160 program and plans to focus efforts on Z944, its novel oral T-type calcium channel modulator in development for the treatment of pain.

[Ripping7]

Looks like they will have to offer more shares and then do another reverse split. Wash rinse repeat. Keep handing them money. This is a joke.

[dubbya]

Wow, this one surprised me. No position, was waiting until after results were announced and dilution, but was optimistic. What a minefield biotech is.

[Paul Wall]

Chapter 11 coming?

[declaes]

Wow... 1,2 crazy

[ospreyeye]

ZLCS TIMBER ALERT: Company to Discontinue Z160 Clinical Development-

Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications. Z160 did not meet the primary endpoint in either of the Phase 2 clinical studies in patients with lumbosacral radiculopathy (LSR) and post-herpetic neuralgia (PHN). Z160 was shown to be generally safe and well-tolerated with no drug-related serious adverse events. Based on these results, Zalicus is discontinuing the Z160 program and plans to focus efforts on Z944, its novel oral T-type calcium channel modulator in development for the treatment of pain.

“Despite its promising preclinical profile, Z160 was unable to translate those results into clinical efficacy. A review of the data demonstrate that both studies were conducted in a rigorous fashion and resulted in adequate exposure of Z160, yet failed to demonstrate a difference in effect from placebo on any endpoint,” said Mark H.N. Corrigan, MD, President and CEO of Zalicus. “There is a significant unmet need for novel and effective non-opioid based pain therapies, and it was our sincere hope that Z160, with its novel mechanism of action, would offer the potential to provide relief to the millions of patients who suffer from chronic neuropathic pain.”

[linie]

new article:

Zalicus Awaits Day of Reckoning, Braces For Key Pain Drug Results

http://www.xconomy.com/boston/2013/11/11/zalicus-awaits-day-reckoning-braces-key-pain-drug-results/

[bigbro1]

New SA article "Key Issues Surrounding The Zalicus Catalyst Trade"

http://seekingalpha.com/article/1822092-key-issues-surrounding-the-zalicus-catalyst-trade?source=feed_f

[linie]

Article: Why Zalicus (ZLCS) Shares Could Make a Big Move in the Days Ahead
In case you haven't already heard, over in the biotech sector many investors are on the edge of their seats waiting for a huge binary event from Zalicus, Inc. (NASDAQ: ZLCS); a NASDAQ listed biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain which could, according to some of the analysts who cover the stock, see share prices soaring from current levels to somewhere between $12 and $18 per share depending on pending clinical data which is set to be released within days.

Read it here: http://finance.yahoo.com/news/why-zalicus-zlcs-shares-could-130847743.html

[linie]

Yes , go greeeeennnn ... 5 $ ... GO

[dubbya]

Tweet this morning posted by Jason Napodano:
"I'm thinking data on Z160 the week of the 18th. Several smart "CNS people" have told me Z160 will fail, so trade wisely people!"

"CNS" is central nervous system.

[jimmc]

Both z160 trials

[dubbya]

Does anyone recall that the Z160 trial would be finished first, but that they would likely wait to announce the results of both at the same time if they had positive news for both? I believe Jason Napodano alluded to this possibility. I'm worried about the results for Z160 now.

[AMOTE1]

LCS
InPlay: Zalicus announces positive results of Z944 Phase 1b clinical study in pain; efficacy signals in inflammatory and neuropathic pain observed; second U.S. patent issues for Z944 providing exclusivity to 2029 Briefing.c

[ECole]

updates given at Rodman renshaw conf

http://www.earningsimpact.com/Transcript/83506/ZLCS/Zalicus-Inc---15th-Annual-Rodman-and-Renshaw-Global-Investment-Conference

[Jukimol]

Another big hint that data from $ZLCS will be awesome and that big pharma will be looking to partner with them again:

http://www.elsevierbi.com/mkt/Conf/TAP2013/PresentingCos

READ ALL THE DETAILS!

[Jukimol]

yes

[peterus]

are you a premin menber from biomedreports ?????

[Jukimol]

Just saw this posted as a tweet by @BioMedReports:

News before its official: Looks like $ZLCS was just awarded a patent
http://patents.justia.com/assignee/zalicus-pharmaceuticals-ltd

[chevelle_69]

http://seekingalpha.com/article/1780822-recent-fda-news-makes-a-zalicus-trade-look-even-more-compelling

[jimmc]

It would be interesting to know what the patient's pain score was initially

[wildbullus]

$ZLCS Animal study showed Z160 equals to 10mg Morphine, Merck study showed some patients had pain relief, one Texas center showed one patient had only pain score of 2. I would think it will work just like prialt, so the both Z160 trials will be very positive.

[chevelle_69]

http://www.insidermedicine.com/archives/CIHR_Video_Dr_Terrance_Snutch_PhD_FRSC_University_of_British_Columbia_Insidermedicine_In_the_Spotlight_5418.aspx

[peterus]

November could be a good month for ZLCS

[peterus]

nice thinking of buying monday

[dubbya]

Biotech red flags list. Good article.

http://www.biotechduediligence.com/1/post/2013/10/5-more-red-flags-biotech-investors-should-heed.html

[peterus]

nice name fedel kastro lol